发布时间 : 星期一 文章简介（华东医药）中英文更新完毕开始阅读f4ef94cf6137ee06eff918ec
杭州华东医药集团有限公司简介
杭州华东医药集团有限公司的前身是创建于1952年的浙江制药厂，后更名为杭州制药二厂、杭州华东制药厂。1992年12月16日，经杭州市经委和体改委批准，在华东制药厂的基础上组建了杭州华东医药（集团）公司，集团包括杭州中美华东制药有限公司、杭州九源基因工程有限公司、浙江华义医药有限公司、埃斯特维华义制药有限公司等20余家企业；1999年12月以杭州中美华东制药有限公司与杭州医药站重组的华东医药股份有限公司5000万A股获准在深交所公开发行。华东医药集团于1996年被列入浙江省政府重点培育的首批十八家大型企业，1999年被国家经贸委确定为全国制造业500强（综合排名第312位）、全国医药100强（综合排名第14位），2005至2010年度浙江省医药行业综合指标排名第1，同时也是杭州市科技示范企业、浙江省科技进步优秀企业、杭州市高新技术开发区区外高新技术企业。2009年华东医药集团下属杭州中美华东制药有限公司、杭州九源基因工程有限公司、浙江华义医药有限公司、杭州朱养心制药有限公司均被认定为国家高新技术企业。2010年整个集团实现销售收入125亿元，资产总值 76亿元，净利润5亿元。
集团目前拥有员工4300人，30%以上为技术人员。其中大专以上学历1703人，博士学历 10人，硕士142人、高级工程师 64人。生物工程研究所、基因工程研究所、合成研究所和中药研发中心是集团的主要药物研究开发机构。研发内容涵盖微生物药物、合成药物和中药，从医药中间体、医药原料至成品贯穿医药领域的全过程。其中尤以化学药制剂见长，拥有免疫抑制、糖尿病等多个在国内专科治疗领域领先的产品线，产品技术获国家、省、市多项科技进步奖。
The predecessor of Hangzhou Huadong Medicine Group Co, Ltd is Zhejiang Pharmaceutical factory established in 1952 and the factory was later renamed as Hangzhou 2nd pharmaceutical factory and Hangzhou Huadong pharmaceutical factory. At 16th, Dec, 1992, approved by Hangzhou municipal economic commission and Hangzhou municipal commission for economic restructuring, based on Huadong Pharmaceutical factory, Hangzhou Huadong Medicine (Group) was incorporated, with more than 20 subsidiaries and joint ventures including Hangzhou Zhongmei Huadong Pharmaceutical Co, Ltd, Hangzhou Jiuyuan Gene-engineering Co., Ltd, Zhejiang Huayi Pharmaceutical Co., Ltd, Esteve Huayi Pharmaceutical Co., Ltd, etc. In Dec, 1999, 50 million A shares of Huadong Medicine Co., Ltd, reorganized based on Hangzhou Zhongmei Huadong Pharmaceutical Co, Ltd and Hangzhou Medicine Station, were first issued in Shenzhen Stock Exchange. In 1996, Huadong Medicine Group was ranked in the first 18 large-size enterprises preferentially supported by Zhejiang provincial government, in 1999, was ranked in China Top 500 (312th) manufacturing industrials by National Economic and Trade Committee, China Top 100 (14th) medical and pharmaceutical enterprise, Top 1 in Zhejiang medical and pharmaceutical industry from 2005 to 2010, model enterprises of science and technology innovation of Hangzhou, excellent model enterprise of science and technology innovation of Zhejiang province and external high-tech enterprise of Hangzhou high-tech industry development zone. In 2009, four subsidiaries of Huadong Medicine Group, Hangzhou Zhongmei Huadong Pharmaceutical Co, Ltd, Hangzhou Jiuyuan Gene-engineering Co., Ltd, Zhejiang Huayi Pharmaceutical Co., Ltd and Hangzhou ZhuYangxin Pharmaceutical Co., Ltd were honored as national high-tech enterprise. In 2010, sales revenue of the group amounts to 12.5 billion Chinese Yuan, the total assets amount to 7.6 billion Yuan and net profit amounts to 500million Yuan.
There are 4300 staffs in the Group, in which more than 37% are technical persons. Among all the staffs, there are 1703 persons with degrees higher than junior college degree, 10 doctors, 142 masters and 64 senior engineers. Bio-engineering institute, gene-engineering institute, synthesis institute and traditional Chinese medicine(TCM) R&D center are main R&D branches of the Group. The R&D scope covers the whole process from intermediate, API to final dosage forms of microbiological products, chemical synthetic products and TCMs. The traditional strength is in chemical dosage
forms, with advanced product pipelines in multiple specific therapeutic fields like immunosuppressants, anti-diabetics, etc. The technologies involved have won plenty of state, provincial and municipal honors for science and technology innovations.